Occurrence of Low-Birth-Weight Babies Heightened in Active-Duty Servicewomen
By Lori Solomon HealthDay Reporter
THURSDAY, April 25, 2024 -- Active-duty servicewomen in the United States appear to have an increased occurrence of low-birth-weight babies compared with nonservice women, according to a review published online April 22 in BMJ Military Health.
Kirsten A.L. Morris and Martin McKee, M.D., from the London School of Hygiene & Tropical Medicine, conducted a systematic literature review to understand the prevalence of preterm delivery, preterm labor, low birth weight, and stillbirth in babies born to active-duty servicewomen in the armed forces.
Based on 21 included studies (650,628 participants; published between 1979 and 2023), the researchers found an increased rate of low birth weight in active-duty servicewomen versus nonservice women. Evidence was insufficient to conclude or rule out whether active-duty servicewomen have increased rates of preterm delivery or preterm labor.
"Active-duty servicewomen may be at increased risk of having a low birth weight baby. However, caution is needed if seeking to generalize the findings beyond the U.S. context," the authors write. "This review highlights a growing need for female-specific research in other armed forces and, specifically, into reproductive health. Such research is necessary to inform military maternity pathways and policies in ways that safeguard mothers and their babies while enhancing military readiness."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.